Tag: revenues

 - Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Pet Oral Care Products Market size & share revenue was valued at approximately USD 2,056.87 Million in 2024 and is expected to reach USD 2,169.79 Million in 2025 and is expected to reach around USD 3,583.11 Million by 2034, at a CAGR of 5.73% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are All4pets, AllAccem Inc., Central Garden & Pet Company, Ceva, Ceva Santé Animale, Cosmos Corporation, Dechra Pharmaceuticals plc, Goran Pharma Pvt. Ltd., Hill’s Pet Nutrition Inc., Imrex Inc., Kane Biotech, Inc., Mars Incorporated, Nestlé Purina PetCare Company (Nestlé S.A.), Petzlife UK, Vetoquinol SA, Virbac and others.

MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA¹ PET² imaging agent, Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).

BASSETT, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) reported today its results of operations for its second quarter ended May 31, 2025.

MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) is today reporting on reaching key operational milestones for Le Mans Ultimate, the official game of the FIA World Endurance Championship and the 24 Hours of Le Mans, and RaceControl, the Company’s matchmaking and online racing system, which provides enhanced access to online features, including championships, extended registration periods, and priority driver reports.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

Data from Orbit and Cosmic studies expected around the end of the year

Talent concentrates in global tech hubs as AI reshapes workforce demand and location strategy

Samsung’s cutting-edge new folding phones now available on America’s Largest Network with the Fastest and Most Reliable 5G